Phosphatidylinositol-3
kinase (PI-3 K) plays a central role in a broad range of
biological effects. However, little is known about its role in
phorbol ester- or
epidermal growth factor (
EGF)-induced signal transduction to the transcriptional machinery of the nucleus and in
tumor promoter-induced cell transformation. We have used JB6 cells to study the role of PI-3 K in 12-O-tetradecanoylphorbol-13-acetate (TPA)- or
EGF-induced
AP-1 activation and
neoplastic cell transformation. We demonstrated that TPA,
EGF and
insulin induce PI-3 K activity in JB6 cells. The induced PI-3 K activity was blocked by a dominant negative mutant of PI-3 K, and by
wortmannin or
LY294002. Blocking of PI-3 K activity by these inhibitors also blocked TPA- or
EGF-induced
AP-1 activity and cell transformation. Furthermore, we have investigated the role of PKC and its
isozymes in the synergistic induction of PI-3 K by TPA and
insulin and found that
bisindolylmaleimide, a PKC inhibitor, inhibits TPA-induced PI-3 K. Overexpression of a dominant negative
PKC epsilon, but not dominant negative PKC alpha, blocks the TPA- or TPA plus
insulin-induced PI-3 K activity.
Inositol hexaphosphate (InsP6) is one of the most promising chemopreventive agents as demonstrated by Shamsuddin et al. and others. InsP6 profoundly inhibits
EGF- or TPA-induced cell transformation and the signal transduction cascade to Erks and
AP-1 activation. InsP6 also inhibits TPA- or
EGF-induced PI-3 K activity in vivo and in vitro. These results suggest that the anticarcinogenesis action of InsP6 may be through inhibition of PI-3 K and inhibition of the
AP-1 pathway. Because InsP6 is a naturally occurring compound with virtually no toxicity, and may be an effective anticarcinogenesis agent in humans, PI-3 K and
AP-1 activities may be useful
biomarkers for the effectiveness of InsP6 in clinical studies.